Avalo Therapeutics, Inc.
AVTXAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Oct 26, 2026 | Oppenheimer | $16.00(+136%) | $6.77 | TheFly | |
| Oct 23, 2026 | BTIG | Julian Harrison | $10.00(+34%) | $7.45 | TheFly |
| Aug 7, 2026 | Guggenheim | $48.00(+157%) | $18.70 | TheFly | |
| Aug 7, 2026 | H.C. Wainwright | $30.00(+60%) | $18.70 | TheFly | |
| Jul 6, 2026 | Leerink Partners | $38.00(+92%) | $19.80 | TheFly | |
| May 14, 2026 | Wedbush | $34.00(+75%) | $19.46 | TheFly | |
| May 14, 2026 | Mizuho Securities | $45.00(+127%) | $19.85 | TheFly | |
| May 14, 2026 | H.C. Wainwright | $35.00(+76%) | $19.85 | TheFly | |
| May 11, 2026 | Piper Sandler | $60.00(+178%) | $21.57 | TheFly | |
| May 6, 2026 | BTIG | $58.00(+257%) | $16.26 | TheFly | |
| Apr 8, 2026 | Wolfe Research | $48.00(+233%) | $14.41 | TheFly | |
| Feb 2, 2026 | Guggenheim | $50.00(+231%) | $15.11 | TheFly | |
| Dec 17, 2025 | Mizuho Securities | Joseph Catanzaro | $39.00(+103%) | $19.25 | TheFly |
| Sep 17, 2025 | H.C. Wainwright | $25.00(+121%) | $11.33 | TheFly | |
| Mar 25, 2025 | Jefferies | Kambiz Yazdi | $23.00(+169%) | $8.54 | TheFly |
| Apr 16, 2024 | Oppenheimer | Leland Gershell | $35.00(+130%) | $15.24 | StreetInsider |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Wedbush | maintain | Outperform | Nov 6, 2026 |
| BTIG | maintain | Buy | Oct 23, 2026 |
| HC Wainwright & Co. | downgrade | Buy →Neutral | Oct 23, 2026 |
| Wedbush | maintain | Outperform | Oct 23, 2026 |
| Guggenheim | downgrade | Buy →Neutral | Oct 23, 2026 |
| HC Wainwright & Co. | maintain | Buy | Aug 7, 2026 |
| Guggenheim | maintain | Buy | Aug 7, 2026 |
| BTIG | maintain | Buy | Jun 16, 2026 |
| Citizens | maintain | Market Outperform | May 14, 2026 |
| Wedbush | maintain | Outperform | May 14, 2026 |
| Mizuho | maintain | Outperform | May 14, 2026 |
| HC Wainwright & Co. | maintain | Buy | May 14, 2026 |
| Piper Sandler | maintain | Overweight | May 11, 2026 |
| BTIG | maintain | Buy | May 6, 2026 |
| Citizens | maintain | Market Outperform | May 6, 2026 |
| Wedbush | maintain | Outperform | May 6, 2026 |
| BTIG | maintain | Buy | Apr 13, 2026 |
| HC Wainwright & Co. | maintain | Buy | Mar 25, 2026 |
| BTIG | maintain | Buy | Mar 24, 2026 |
| HC Wainwright & Co. | maintain | Buy | Jan 15, 2026 |
| BTIG | maintain | Buy | Sep 29, 2025 |
| HC Wainwright & Co. | maintain | Buy | Sep 17, 2025 |
| HC Wainwright & Co. | maintain | Neutral | Mar 20, 2025 |
| Oppenheimer | upgrade | Perform →Outperform | Apr 16, 2024 |
| RBC Capital | downgrade | Outperform →Sector Perform | Jun 26, 2023 |
Earnings History
Next report: Mar 22, 2027 · EPS est. $-0.59| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 5, 2026 | $-0.34 | $-0.59 | — | — |
| Aug 6, 2026 | $-0.83 | $-0.58 | — | — |
| May 13, 2026 | $-0.98 | $-1.00 | — | — |
| Mar 23, 2026 | $-0.74 | $-1.54 | $79.5K | — |
| Nov 6, 2025 | $-2.19 | $-1.67 | — | — |
| Aug 7, 2025 | $-1.92 | $-1.43 | — | — |
| May 12, 2025 | $-1.25 | $-1.07 | — | — |
| Mar 27, 2025 | $-2.30 | $-1.29 | $200.0K | $300.0K |
News
Advancing abdakibart toward a registrational Phase 3 program in hidradenitis suppurativa, with initiation planned for the first half of 2027 Advancing AVTX-010, a next-generation, long-acting anti-IL-1β antibody, toward an Investigational New Drug submission in the first half of 2027 Cash, cash equivalents and investments of $462.8 million as of September 30, 2026 , expected to fund operations into 2029 WAYNE, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clin…
WAYNE, Pa., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced that management will participate in the following investor conferences:
Avalo Therapeutics' positive LOTUS results now support a pivotal trial, and its monthly dosing gives it a potential differentiating factor in HS. Their balance sheet has enough runway to meet their upcoming milestones as well. AVTX-010 offers follow-on potential, but its planned IND submission means that it's still years away from becoming a meaningful value driver for AVTX.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Avalo Therapeutics, Inc. (NASDAQ: AVTX - Get Free Report) hit a new 52-week low on Wednesday. The stock traded as low as $11.99 and last traded at $12.01, with a volume of 1,648,996 shares. The stock had previously closed at $13.24. Wall Street Analysts Forecast Growth A number of equities analysts have recently issued reports on
WAYNE, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced the grant of inducement equity awards to three new employees. The Compensation Committee of the Board of Directors of Avalo approved the grants of nonstatutory stock options to purchase an aggregate of 101,600 shares of common stock (the “Options”) …
WAYNE, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced a late-breaker oral presentation and poster at the upcoming EADV Congress 2026, to be held in Vienna, Austria from September 30-October 3, 2026.
Avalo Therapeutics, Inc. (NASDAQ: AVTX - Get Free Report) CFO Christopher Sullivan sold 12,394 shares of Avalo Therapeutics stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $16.33, for a total value of $202,394.02. Following the completion of the transaction, the chief financial officer owned 39,900 shares of
WAYNE, Pa., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced the grant of inducement equity awards to six new employees. The Compensation Committee of the Board of Directors of Avalo approved the grants of nonstatutory stock options to purchase an aggregate of 78,000 shares of common stock (the “Options”) as …
Avalo Therapeutics (AVTX) is now a well-funded, registrational-stage biotech with validated Phase II data for abdakibart in hidradenitis suppurativa (HS). Abdakibart demonstrated statistically significant HiSCR75 response rates and clean safety, with monthly dosing and efficacy across both biologic-experienced and naive patients. AVTX's $472M cash position secures operations into 2029, reducing near-term dilution risk and enhancing negotiating leverage for Phase 3 and beyond.
WAYNE, Pa., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced that management will participate in the following investor conferences: